A new genomic test implemented by the NHS significantly reduces the time for brain tumour diagnosis from weeks to just hours. This advancement allows patients to begin treatment sooner, alleviating prolonged uncertainty. The test analyzes the genetic makeup of tumour samples, providing crucial information while patients are still in surgery.
The pilot program will take place in five specialist centres across England, with plans for expansion. This rapid testing could not only enhance patient care but also improve surgical decision-making and access to clinical trials, marking a significant shift in brain tumour management.
Watch for the pilot's impact on surgical practices and patient outcomes as it rolls out in five NHS centres. The rapid genomic test could redefine treatment pathways, enabling quicker access to clinical trials and personalized therapies for brain tumour patients.